Full-Time

Product Engineer – New College Graduate

Posted on 3/22/2024

Ultima Genomics

Ultima Genomics

201-500 employees

High-throughput genomic sequencing services

Compensation Overview

$78k - $85k/yr

Entry

Fremont, CA, USA

Category
Product
Required Skills
Python
Requirements
  • BS or MS in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Physics, Molecular Biology, or Biology with a strong mechanical intuition and proven hands-on projects
  • Experience working in a biological lab or controlled environment
  • Experience with Python or MATLAB
Responsibilities
  • Develop pilot manufacturing strategies for current goals and future scale-up
  • Track and manage system configuration and Engineering Change Order processes
  • Understand and troubleshoot the instrumentation hardware at a component, subsystem, and system level
  • Characterize performance of hardware modules and sub-components such as fluid handling and opto-mechanical systems
  • Develop methods using the latest tools and techniques to collect and analyze data for optimization of hardware configurations and system processes
  • Establish an understanding of module-module interactions, quantify system performance and reliability
  • Identify potential design improvements, run tests to measure their impact, and drive their adoption across various development teams
  • Integrate research and development procedures to customer field units
  • Develop Field Service Documentation and rollout strategies
  • Monitor and develop troubleshooting strategies to resolve customer issues
  • Perform installation checklists, travel to customer sites to troubleshoot or upgrade field units at customer sites
  • Push the development and refinement of IQ/OQ/PQ and Preventative Maintenance procedures
  • Support the successful transfer of our technology to customer sites

Ultima Genomics improves human health through advanced genomic sequencing technologies, processing large volumes of genetic data to provide insights into biology and diseases. Its unique sequencing architecture allows for extensive data collection, detection of small genetic variations, and routine testing for early disease detection. This focus on breadth, depth, and frequency sets Ultima Genomics apart from competitors, providing clients with high-quality genomic information. The company's goal is to empower researchers and healthcare professionals to achieve breakthroughs in understanding and treating diseases.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$604.2M

Headquarters

Newark, New Jersey

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • UG 100 Solaris platform reduces sequencing costs by 20%, increasing accessibility.
  • Partnerships with Myriad and NeoGenomics expand clinical applications in oncology and genomics.
  • Increased demand for single-cell sequencing drives collaborations like the Billion Cells Project.

What critics are saying

  • Competition from Illumina threatens Ultima's market share in genomic sequencing.
  • Rapid AI advancements by AWS and Compugen may outpace Ultima's technology.
  • Psomagen's collaboration with Chan Zuckerberg Initiative may divert clients from Ultima.

What makes Ultima Genomics unique

  • Ultima Genomics offers ultra-high-throughput sequencing with the UG 100 platform.
  • The company excels in breadth, depth, and frequency of genomic data collection.
  • Ultima's technology supports groundbreaking projects like the UK Biobank proteomics study.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Holidays

Paid Vacation

Employee Assistance Program

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

0%
PR Newswire
May 5th, 2025
Psomagen Selected As Key Service Provider, Will Utilize Ultima Genomics' Ug 100™ Sequencer To Accelerate Chan Zuckerberg Initiative'S Billion Cells Project

ROCKVILLE, Md., May 5, 2025 /PRNewswire/ -- Psomagen Inc., a multiomics service laboratory serving academic, pharma, biotech, and clinical customers, will join the Billion Cells Project led by the Chan Zuckerberg Initiative (CZI). The Billion Cells Project aims to develop a landmark single-cell dataset of one billion cells that will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function. Psomagen has begun providing services to participating researchers in April. The project includes collaborations with several other technology partners, including Ultima Genomics, 10x Genomics and Scale Biosciences. Su Hong, CEO of Psomagen, says, "This project represents a transformative step in biomedical research, enabling the identification of novel therapeutic targets and guiding drug development with unparalleled precision. By leveraging AI-powered analysis on vast single-cell datasets, we aim to accelerate the discovery of new ways to restore diseased cells to health

BioPharmaTrend
Apr 29th, 2025
NeoGenomics Adopts Ultima Genomics Platform to Expand Sequencing-Based Oncology Diagnostics

NeoGenomics has partnered with Ultima Genomics to integrate the UG 100 sequencing platform into its Cambridge, UK innovation center, aiming to develop a new range of clinical oncology tests.

HTXT
Apr 9th, 2025
How AI is being used to find a cure for Parkinson's Disease

Here, AWS is working with the likes of California-based company Ultima Genomics, which has developed software, algorithms and training of its AI models on AWS for its next-generation DNA sequencer.

Duniata
Apr 6th, 2025
Ultima genomics offers 3 trillion free sequencing reads to support the scientific community

Ultima Genomics, developer of an ultra-high-throughput sequencing architecture, today announced the launch of its "Count on Us" initiative.

PR Newswire
Feb 26th, 2025
Ultima Genomics Increases Output By Over 50% And Lowers Sequencing Costs By A Further 20% With The Introduction Of Ug 100 Solaris(Tm)

Commercial launch of UG 100 Solaris which includes new chemistry, software, and simplified workflows for the UG 100 sequencing platform, now with expanded applications support and integration with leading 'omics' technologies. Over 50% increase in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. Increased sensitivity with 5X yield improvement for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA (1/5th of the cfDNA found in a standard tube of blood)

INACTIVE